ArticleScience progress
Association between hemoglobin-to-red cell distribution width ratio and critically ill patients with atrial fibrillation: A retrospective cohort study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo investigate the association between the hemoglobin-to-red cell distribution width ratio (HRR) and in-hospital and 30-day mortality among critically ill patients with atrial fibrillation (AF).MethodsWe conducted a retrospective cohort study of AF patients from the MIMIC-III and IV databases. Patients were divided into HRR quartiles. The primary outcomes were in-hospital and 30-day mortality. Kaplan-Meier survival curves, dose-response analysis, and multivariable regression models assessed HRR-mortality associations, with subgroup and sensitivity analyses for robustness.ResultsAmong 21,625 patients (median age 75.0 years, 59.8% male), in-hospital and 30-day mortality rates were 14.8% and 24.5%. Mortality was inversely related to HRR, with Q1 showing higher risk than Q4 (in-hospital: 20.0% vs. 12.7%). Dose-response analysis revealed linear HRR-mortality relationships. In adjusted models, each 0.1-unit HRR increase reduced risk by 37% for in-hospital mortality (OR: 0.63, 95% CI: 0.60-0.66) and 31% for 30-day mortality (HR: 0.69, 95% CI: 0.67-0.71). Compared with Q1, Q4 was associated with 79% lower adjusted odds of in-hospital mortality and a 71% lower adjusted hazard of 30-day mortality. Subgroup analyses confirmed consistent protective associations, with modification by age and myocardial infarction.ConclusionsHigher HRR was independently associated with lower in-hospital and 30-day mortality in critically ill patients with atrial fibrillation. Higher HRR associates with improved survival, supporting its potential role as a complementary marker for risk assessment and prognostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.